

TBVI Symposium 2024 January 30-31, 2024

Tuesday January 30, 2024 (Maison des congrès)

14.00-14.05 Welcome and Opening: Gerald Voss, Executive Director ad interim, TBVI

1. Fundamental and applied research and novel technologies to innovate the TB vaccine pipeline

Novel insights in mucosal vaccine administration and spatial-temporal patterns of the local immune response in and beyond TB (chair: Olivier Neyrolles)

14:05-14.10	Introduction (Olivier Neyrolles)
14.10-14.30	Brittany Hartwell - University Minnesota, Minneapolis: "Harnessing albumin hitchhiking for enhanced uptake of mucosal vaccines against infectious disease"
14.30-14.50	David Schreiner - University Basel: "Space, the final frontier?"
14.50-15.10	Emma Lefrancais - CNRS-IPBS, Toulouse: "Intravital imaging of lung immune responses"
15:10-15.30	Klaas van Gisbergen - Champalimaud Foundation, Lisbon: "Immunological Memory of the Tissues"
15.30-15.40	Young Scientist Awards (Frank Verreck)
15:40-15.55	Paul Ogongo - University of California San Francisco: "Distinct <i>Mtb</i> antigens under diversifying evolutionary selection induce Th17 responses in controlled human tuberculosis"
15.55-16.10	Discussion and Summary (All, Olivier Neyrolles)

16.10-16.40 Coffee break and Group photo

Joint dinner

20.00

Novel TB vaccine candidates: Innovative approaches, in vivo-/in vitro-models, tools and technologies (chair: Andrea Cooper)

16.40-16.45	Introduction (Andrea Cooper)
16.45-17.05	David Lewinsohn - OHS University, Portland: "DURTS as a Target for Vaccination"
17.05-17.25	Björn Corleis - FLI, Isle of Riems: "Inter-species comparison of immune responses to novel mucosal vaccine concepts"
17.25-17.45	Tom Scriba - SATVI, Cape Town: "Inflammatory and T cell biomarkers of disease progression or control of <i>Mtb</i> "
17.45-18.05	Thomas Lindenstrøm - Statens Serum Institute, Copenhagen: "Vaccine-promoted HEVs and T cell trafficking in the <i>Mtb</i> infected lung"
18.05-18.20	Juliane Hübner - TissUse, Berlin: "TB Organoid Model – towards an MPS-based assay to test TB vaccines and treatment modalities"
18.20-18.35	Helen McShane - Oxford University: "Controlled Human Infection Model (CHIM)"
18.35-18.45	Discussion and Summary (All, Andrea Cooper)
18.45-18.50	Wrap-up & summary, outlook to Wednesday (Andrea Cooper, Olivier Neyrolles and Elly van Riet)
19.00-20.00	Reception



TBVI Symposium 2024 January 30-31, 2024

Wednesday January 31, 2024 (Maison des congrès)

08.15-08.20 Welcome and programme of the day (Elly van Riet - TBVI)

2. Accelerating Clinical Development

08.20-08.30	Introduction (Helen McShane)
08.30-08.45	Mark Hatherill - University of Cape Town: "Overview TB Vaccine Clinical Pipeline"
08.45-09.00	Carlos Martin - University Zaragoza: "Live attenuated TB vaccine candidate MTBVAC"
09.00-09.15	Sina Brückner - SLS Europe, Hannover: "Updates on the VPM1002 development"
09.15-09.30	Andy Tran - St George's University of London: "Development of a Novel Self-Adjuvanting Vaccine Platform for TB"
09.30-09.45	Ann Ginsberg - BMGF, Seattle: "M72/AS01E update"
09.45-10.00	Alvaro Borges - Statens Serum Institute, Copenhagen: "The TB vaccine H56:IC31: phase 2 prevention of recurrence trial"
10.00-10.30	Coffee break
10.30-11.00	Pragmatic design of efficacy trials –
	Interactive debate with Mark Hatherill and Frank Cobelens, moderated by Helen McShane

3. Enablers to ensure public health impact

11.00-11.15	Debbie King - Wellcome Trust, London
11.15-11.30	Jean Marie Habarugira - Global Health EDCTP3, Brussels: "Current Research and Innovation Strategy"
11.30-11.45	Ann Ginsberg - BMGF, Seattle: "TB Vaccine program at BMGF – current and planned activities"
11.45-12.00	Mphatso Phiri - Liverpool School of Tropical Medicine: " <i>Mtb</i> infection prevalence: implications for estimating population impact of pre- & post-exposure TB vaccines"
12.00-12.15	Birgitte Giersing - WHO, Geneva: "WHO activities to accelerate TB vaccine development and use"
12.15-12.20	Helen McShane - Oxford University: "The Validate Network"
12.20-12.30	Summary and closure (Elly van Riet)